About N-terminal EF-hand calcium-binding protein 1
N-terminal EF-hand calcium-binding protein 1 (NECAB1) is a protein
from Homo sapiens identified by UniProt accession
Q8N987, 351 residues long.
MolForge cross-references it against 0 known binders and
56 disease associations.
Target properties
| Protein name | N-terminal EF-hand calcium-binding protein 1 |
| UniProt accession | Q8N987 |
| Gene | NECAB1 |
| Organism | Homo sapiens |
| Length | 351 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (56)
Diseases linked to this target (Open Targets).
- body fat percentage · score 0.32
- smoking behaviour measurement · score 0.22
- age at first sexual intercourse measurement · score 0.21
- self reported educational attainment · score 0.19
- serum metabolite measurement · score 0.19
- smoking status measurement · score 0.15
- smoking initiation · score 0.11
- hematocrit · score 0.10
- hemoglobin measurement · score 0.07
- insomnia measurement · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q8N987-F1 | alphafold | PREDICTED | 79.11 | — |
Amino-acid sequence (351 residues)
MEDSQETSPS SNNSSEELSS ALHLSKGMSI FLDILRRADK NDDGKLSFEE FKAYFADGVL SGEELHELFH TIDTHNTNNL DTEELCEYFS QHLGEYENVL AALEDLNLSI LKAMGKTKKD YQEASNLEQF VTRFLLKETL NQLQSLQNSL ECAMETTEEQ TRQERQGPAK PEVLSIQWPG KRSSRRVQRH NSFSPNSPQF NVSGPGLLEE DNQWMTQINR LQKLIDRLEK KDLKLEPPEE EIIEGNTKSH IMLVQRQMSV IEEDLEEFQL ALKHYVESAS SQSGCLRISI QKLSNESRYM IYEFWENSSV WNSHLQTNYS KTFQRSNVDF LETPELTSTM LVPASWWILN N
Explore N-terminal EF-hand calcium-binding protein 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets